Science7 publishers2 min readPublished
Deisseroth, Nagel and Hegemann win the 2026 medicine Nobel for controlling cells with light
Karl Deisseroth, Georg Nagel and Peter Hegemann won the 2026 medicine Nobel for optogenetics, the control of cells with light and genetics. It goes to a laboratory method, unlike the discoveries and treatments Scientific American cites from the prize's 125-year record.
The Scientist · Science desk
Drafted by a language model from the sources cited here and checked against its claim ledger before publication. How we use AISend a correction
What happened
- The citation, as Scientific American reported it, credits the three with the discovery of rhodopsin as well as optogenetics.
- The prize, first given in 1901, has been awarded 116 times to 232 winners, by Scientific American's count.
- The three previous prizes went to research behind the COVID-19 mRNA vaccine in 2023, microRNA in 2024 and peripheral immune tolerance in 2025.
- Scientific American filed its report as breaking news on Oct. 5, 2026, with a note that it would be updated.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- precedent A prize for an ability to control cells puts a research tool on the same footing as discoveries and treatments, giving methods that open new experiments a recent model for recognition.
- constraint The citation describes controlling cells, not treating patients, so the award on its own is no evidence that optogenetics works as a therapy in people.
- decision Anyone forecasting medicine Nobels from commercial impact has one product-linked winner in the last four to go on, a thin base for that approach.
Optogenetics, in Scientific American's one-line definition, is an ability: the control of cells using light and genetics [3]. The magazine sorts the prize's past into three groups [5][6][7]. That definition does not fit cleanly into any of them.
The first group is discoveries, such as insulin, penicillin, blood groups and the molecular structure of DNA [5]. The second is understanding of biological processes, including how neurons work, how malaria spreads and the role of human papillomavirus in cervical cancer [6]. The third is treatments, among them in vitro fertilization and the first antibiotic for tuberculosis [7].
I think optogenetics is closest to an instrument. What it is worth to medicine depends on the experiments other researchers run with it. The breaking report [9] does not say which cells the method has been used on, what those experiments found, or what other work was in contention for the prize.
Counting this year, only the 2023 award among the last four is tied to a medical product [4]. Four years is too short a run to call a trend.
Three laureates is above the prize's historical average. Divide Scientific American's count of winners by its count of awards and the result is two per prize [1], so this year's split runs one above it [2]. The thing this doesn't tell you is whether three-way splits have become more common lately, since the average covers 125 years of awards [3].
One detail is unsettled in the report as filed. Its headline gives the second laureate's first name as Georg, and its text gives George [10].
What to watch
- The full prize citation and background material, which would say which proteins and experiments the award rests on.
- Scientific American's updated report, including which spelling of Nagel's first name it settles on.